- Home
- IMUX
IMUX
Immunic Inc.
as 12-18-2024 10:38am EST
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 100.0M | IPO Year: | N/A |
| Target Price: | $12.67 | AVG Volume (30 days): | 721.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.97 - $2.11 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunic Inc. (IMUX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rudick Richard Alan | IMUX | Director | Nov 12 '24 | Buy | $1.15 | 87,300 | $100,368.81 | 87,300 |
Latest Immunic Inc. News
IMUX Breaking Stock News: Dive into IMUX Ticker-Specific Updates for Smart Investing
ACCESSWIRE
15 days ago
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
PR Newswire
22 days ago
Immunic, Inc. to Participate in Investor Conference in December
Simply Wall St.
a month ago
Insider Buys Additional US$100k In Immunic Stock
TipRanks
a month ago
Immunic announces publication of IMU-856 data
PR Newswire
a month ago
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
GuruFocus.com
a month ago
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
Associated Press Finance
a month ago
Immunic: Q3 Earnings Snapshot
PR Newswire
a month ago
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Compare IMUX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMUX Immunic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.